Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 54 | 2024 | 20985 | 2.820 |
Why?
|
| Immunoconjugates | 9 | 2024 | 953 | 1.820 |
Why?
|
| Cyclin-Dependent Kinase 4 | 9 | 2023 | 556 | 1.780 |
Why?
|
| Cyclin-Dependent Kinase 6 | 7 | 2022 | 345 | 1.730 |
Why?
|
| Camptothecin | 6 | 2024 | 590 | 1.360 |
Why?
|
| Neoadjuvant Therapy | 12 | 2023 | 2821 | 1.350 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2023 | 5662 | 0.880 |
Why?
|
| Receptor, erbB-2 | 14 | 2024 | 2553 | 0.860 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 17 | 2024 | 11729 | 0.770 |
Why?
|
| Indazoles | 1 | 2022 | 302 | 0.710 |
Why?
|
| Receptors, Estrogen | 10 | 2024 | 2204 | 0.700 |
Why?
|
| Aminopyridines | 6 | 2021 | 570 | 0.540 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2021 | 1517 | 0.460 |
Why?
|
| Cell Cycle | 3 | 2023 | 2929 | 0.450 |
Why?
|
| Piperidines | 1 | 2022 | 1656 | 0.440 |
Why?
|
| Carcinoma | 2 | 2023 | 2328 | 0.440 |
Why?
|
| Standard of Care | 1 | 2017 | 550 | 0.430 |
Why?
|
| Neutropenia | 2 | 2017 | 884 | 0.420 |
Why?
|
| Purines | 5 | 2019 | 605 | 0.410 |
Why?
|
| Retinoblastoma Protein | 1 | 2016 | 671 | 0.400 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2021 | 3512 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2024 | 5292 | 0.380 |
Why?
|
| Estrogen Receptor alpha | 4 | 2024 | 581 | 0.350 |
Why?
|
| Ketones | 2 | 2021 | 183 | 0.340 |
Why?
|
| Furans | 2 | 2021 | 200 | 0.340 |
Why?
|
| Female | 61 | 2024 | 391875 | 0.340 |
Why?
|
| Receptors, Progesterone | 4 | 2021 | 1128 | 0.320 |
Why?
|
| Antineoplastic Agents | 7 | 2023 | 13616 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 3 | 2024 | 2805 | 0.300 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 1588 | 0.300 |
Why?
|
| Humans | 72 | 2024 | 760437 | 0.280 |
Why?
|
| Disease-Free Survival | 5 | 2021 | 6813 | 0.270 |
Why?
|
| Telemedicine | 1 | 2023 | 3027 | 0.260 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2024 | 9267 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3080 | 0.260 |
Why?
|
| Mammography | 1 | 2016 | 2426 | 0.250 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3200 | 0.250 |
Why?
|
| Mass Screening | 2 | 2020 | 5424 | 0.240 |
Why?
|
| Benzimidazoles | 2 | 2021 | 855 | 0.230 |
Why?
|
| Educational Measurement | 1 | 2011 | 1250 | 0.230 |
Why?
|
| Patient Readmission | 2 | 2016 | 3249 | 0.230 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2024 | 70 | 0.230 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 1890 | 0.210 |
Why?
|
| Neoplasm Metastasis | 8 | 2024 | 4903 | 0.200 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2011 | 1066 | 0.200 |
Why?
|
| Neoplasm, Residual | 3 | 2024 | 1008 | 0.200 |
Why?
|
| Ki-67 Antigen | 1 | 2023 | 629 | 0.190 |
Why?
|
| Clinical Trials as Topic | 6 | 2021 | 7996 | 0.190 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 5663 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2021 | 326 | 0.170 |
Why?
|
| Breast Neoplasms, Male | 1 | 2021 | 219 | 0.160 |
Why?
|
| Antigens, Neoplasm | 2 | 2024 | 1994 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2024 | 940 | 0.160 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 628 | 0.160 |
Why?
|
| Gene Fusion | 1 | 2021 | 354 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 256 | 0.150 |
Why?
|
| Students, Medical | 1 | 2011 | 1930 | 0.150 |
Why?
|
| Prognosis | 7 | 2024 | 29551 | 0.150 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2024 | 2860 | 0.150 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 101 | 0.150 |
Why?
|
| Middle Aged | 20 | 2024 | 220382 | 0.130 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2018 | 507 | 0.130 |
Why?
|
| Treatment Outcome | 8 | 2024 | 64591 | 0.130 |
Why?
|
| Piperazines | 4 | 2020 | 2519 | 0.130 |
Why?
|
| Fluorouracil | 1 | 2020 | 1637 | 0.130 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 11096 | 0.130 |
Why?
|
| Paclitaxel | 2 | 2023 | 1732 | 0.130 |
Why?
|
| Mastectomy | 2 | 2021 | 1822 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 799 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2024 | 23397 | 0.120 |
Why?
|
| Hypothermia, Induced | 1 | 2020 | 756 | 0.120 |
Why?
|
| Postmenopause | 3 | 2019 | 2513 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2023 | 8611 | 0.120 |
Why?
|
| Histone Deacetylases | 1 | 2019 | 719 | 0.120 |
Why?
|
| Stomatitis | 1 | 2017 | 271 | 0.120 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2016 | 305 | 0.110 |
Why?
|
| Radiation Oncology | 1 | 2020 | 561 | 0.110 |
Why?
|
| Quality of Life | 4 | 2022 | 13338 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 1624 | 0.110 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 1146 | 0.110 |
Why?
|
| Autopsy | 1 | 2017 | 1005 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 1605 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2017 | 1415 | 0.100 |
Why?
|
| Retrospective Studies | 10 | 2024 | 80430 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 1403 | 0.100 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2024 | 132 | 0.100 |
Why?
|
| Age Factors | 3 | 2018 | 18379 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2018 | 2215 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2020 | 2326 | 0.100 |
Why?
|
| Pyridines | 3 | 2019 | 2868 | 0.100 |
Why?
|
| Mutation | 9 | 2024 | 30025 | 0.100 |
Why?
|
| Informed Consent | 1 | 2018 | 1006 | 0.100 |
Why?
|
| Adult | 15 | 2024 | 220781 | 0.090 |
Why?
|
| Aged | 16 | 2024 | 168840 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2011 | 5866 | 0.090 |
Why?
|
| Forecasting | 1 | 2020 | 2925 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2023 | 3596 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 2058 | 0.090 |
Why?
|
| Pandemics | 2 | 2020 | 8623 | 0.090 |
Why?
|
| Phthalazines | 2 | 2024 | 382 | 0.080 |
Why?
|
| Patient Participation | 1 | 2018 | 1442 | 0.080 |
Why?
|
| Aromatase Inhibitors | 2 | 2024 | 511 | 0.080 |
Why?
|
| Burns | 1 | 2020 | 1863 | 0.080 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5332 | 0.080 |
Why?
|
| Survival Rate | 3 | 2021 | 12698 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 1889 | 0.080 |
Why?
|
| RNA | 1 | 2018 | 2721 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2017 | 10075 | 0.070 |
Why?
|
| Neoplasms | 3 | 2022 | 22083 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2017 | 1909 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 4879 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 39078 | 0.070 |
Why?
|
| Biopsy | 1 | 2018 | 6765 | 0.070 |
Why?
|
| Genomics | 4 | 2023 | 5806 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 7817 | 0.060 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 3876 | 0.060 |
Why?
|
| Recurrence | 1 | 2017 | 8466 | 0.060 |
Why?
|
| Logistic Models | 2 | 2016 | 13240 | 0.060 |
Why?
|
| Schools, Medical | 1 | 2011 | 878 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2018 | 5487 | 0.060 |
Why?
|
| Estrogens | 2 | 2021 | 1519 | 0.060 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2024 | 106 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 7380 | 0.060 |
Why?
|
| Decision Making | 1 | 2016 | 3923 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2018 | 3421 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 3190 | 0.050 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2023 | 330 | 0.050 |
Why?
|
| Motivation | 1 | 2011 | 2006 | 0.050 |
Why?
|
| Registries | 1 | 2017 | 8216 | 0.050 |
Why?
|
| Receptor, erbB-3 | 1 | 2021 | 143 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2023 | 330 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 16945 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10180 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 897 | 0.040 |
Why?
|
| Annexin A6 | 1 | 2018 | 4 | 0.040 |
Why?
|
| United States | 3 | 2024 | 72202 | 0.040 |
Why?
|
| Hormones | 1 | 2023 | 867 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 23953 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2011 | 3728 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2024 | 1600 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2023 | 54339 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2021 | 653 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2021 | 733 | 0.040 |
Why?
|
| Steroids | 1 | 2023 | 928 | 0.040 |
Why?
|
| Workflow | 1 | 2022 | 851 | 0.040 |
Why?
|
| Androstadienes | 1 | 2019 | 348 | 0.040 |
Why?
|
| Scalp | 1 | 2020 | 389 | 0.040 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2017 | 64 | 0.040 |
Why?
|
| Anxiety | 1 | 2011 | 4558 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 604 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2024 | 4010 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2021 | 1254 | 0.030 |
Why?
|
| Fasting | 1 | 2022 | 1600 | 0.030 |
Why?
|
| Alopecia | 1 | 2020 | 411 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2011 | 4777 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1089 | 0.030 |
Why?
|
| Menopause | 1 | 2023 | 1645 | 0.030 |
Why?
|
| Genotype | 2 | 2021 | 12976 | 0.030 |
Why?
|
| Fatigue | 1 | 2022 | 1550 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2019 | 1086 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 2073 | 0.030 |
Why?
|
| Risk Factors | 3 | 2018 | 74055 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 13312 | 0.030 |
Why?
|
| Graft vs Host Disease | 2 | 2017 | 3028 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2019 | 774 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 58859 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 59068 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2018 | 3603 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2023 | 5236 | 0.020 |
Why?
|
| Breast | 1 | 2021 | 1962 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 4108 | 0.020 |
Why?
|
| Depression | 1 | 2011 | 8104 | 0.020 |
Why?
|
| Fear | 1 | 2020 | 1471 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2022 | 2318 | 0.020 |
Why?
|
| Social Support | 1 | 2020 | 2167 | 0.020 |
Why?
|
| Male | 5 | 2021 | 360035 | 0.020 |
Why?
|
| Fever | 1 | 2016 | 1618 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 2911 | 0.020 |
Why?
|
| Proteins | 1 | 2023 | 6033 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2017 | 4808 | 0.020 |
Why?
|
| Genome, Human | 1 | 2021 | 4423 | 0.020 |
Why?
|
| Massachusetts | 1 | 2021 | 8826 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3631 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2021 | 41366 | 0.020 |
Why?
|
| Cytokines | 1 | 2021 | 7377 | 0.020 |
Why?
|
| Adolescent | 1 | 2014 | 88196 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 9533 | 0.020 |
Why?
|
| Disease Progression | 1 | 2023 | 13484 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9176 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 9410 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 10759 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2019 | 12320 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2018 | 14397 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 22121 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 6475 | 0.010 |
Why?
|
| Animals | 2 | 2024 | 168253 | 0.010 |
Why?
|
| Incidence | 1 | 2016 | 21322 | 0.010 |
Why?
|
| Child | 1 | 2023 | 80086 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 39947 | 0.010 |
Why?
|
Concepts
(199)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(168)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_